SCHEMBL3465799

SCHEMBL3465799

NCC1CCC(C(N)=O)CC1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLG P00747 1/20 0.67
PLAT P00750 1/20 0.67
LMNA P02545 1/20 0.67
SMN1; SMN2 Q16637 2/20 0.43
CYP2D6 P10635 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
GAA P10253 1/20 0.38
F2 P00734 1/20 0.38
ALOX5 P09917 1/20 0.38
NCF1 P14598 1/20 0.36
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35
ATM Q13315 1/20 0.35
ITGB3 P05106 1/20 0.35
ITGA2B P08514 1/20 0.35
ANPEP P15144 1/20 0.34
ENPEP Q07075 1/20 0.34
TSHR P16473 1/20 0.33
KDM1A O60341 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10489690 1.00 PLG (0.67) PLGPLATLMNASMN1; SMN2CYP2D6
SCHEMBL1655177 1.00 PLG (0.67) PLGPLATLMNASMN1; SMN2CYP2D6
Hydrochloric Acid SCHEMBL8595447 0.98 PLG (0.64) PLGPLATLMNASMN1; SMN2CYP2D6
Hydrochloric Acid SCHEMBL8595452 0.98 PLG (0.64) PLGPLATLMNASMN1; SMN2CYP2D6
SCHEMBL3629440 0.86 PLG (0.56) PLGPLATLMNASMN1; SMN2CYP2D6
Carbamic Acid SCHEMBL11044735 0.81
SCHEMBL8897842 0.81 LMNA (0.45) PLGPLATLMNASMN1; SMN2CYP2D6
Cyclopropanecarboxylic Acid Amide SCHEMBL6927157 0.81 SMN1; SMN2 (0.50) PLGPLATLMNASMN1; SMN2CYP2D6
Cyclopropanecarboxylic Acid Amide SCHEMBL5661 0.81
SCHEMBL9797557 0.81 SMN1; SMN2 (0.50) PLGPLATLMNASMN1; SMN2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264411-A1 FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS UCB PHARMA S.A. (BE) 2009-10-22 US claimed
JP-1083056-A None JP disclosed
JP-9255542-A None JP disclosed
JP-9255521-A None JP disclosed
JP-6072843-A None JP disclosed
JP-2025417-A None JP disclosed
JP-6087810-A None JP disclosed
JP-1026542-A None JP disclosed
US-20210393809-A1 LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PSMA-EXPRESSING CANCERS Universität Heidelbert (DE) 2021-12-23 US disclosed
CN-113631144-A Cosmetic containing ultraviolet wavelength conversion substance and medicinal agent 株式会社资生堂 2021-11-09 CN disclosed
WO-1997046250-A1 METHODS OF MODIFYING FEEDING BEHAVIOR, COMPOUNDS USEFUL IN SUCH METHODS, AND DNA ENCODING A HYPOTHALAMIC ATYPICAL NEUROPEPTIDE Y/PEPTIDE YY RECEPTOR (Y5) SYNAPTIC PHARMACEUTICAL CORPORATION (US) 1997-12-11 WO disclosed
US-5690914-A TRANEXAMIC ACID DERIVATIVES FOR DEPIGMENTATION SHISEIDO CO., LTD (JP) 1997-11-25 US disclosed
JP-H09255542-A COMPOSITION FOR ORAL CAVITY APPLICATION SHISEIDO CO LTD 1997-09-30 JP disclosed
JP-H09255521-A SEBUM SUPPRESSING AGENT SHISEIDO CO LTD 1997-09-30 JP disclosed
WO-1997020823-A2 2-AMINO QUINAZOLINE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 1997-06-12 WO disclosed
JP-H0687810-A 4-@(3754/24)AMINOMETHYL)CYCLOHEXANECARBOXAMIDE DERIVATIVE SUNTORY LTD 1994-03-29 JP disclosed
JP-H0672843-A SKIN EXTERNAL PREPARATION SHISEIDO CO LTD 1994-03-15 JP disclosed
EP-0585130-A2 External preparation for skin containing a depigmentation agent SHISEIDO COMPANY LIMITED (JP) 1994-03-02 EP disclosed
JP-H0225417-A ANTITUMOR AGENT ASAHI CHEM IND CO LTD 1990-01-26 JP disclosed
JP-S6426542-A 4-AMINOMETHYLCYCLOHEXANECARBOXYLIC ACID AMIDE AND ACID ADDITION SALT THEREOF ASAHI CHEMICAL IND 1989-01-27 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264411-A1 FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS MAPK15, MOK, MAPK14 PLG 3922/4885PLAT 3066/4885LMNA 4755/4885
US-20210393809-A1 LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PSMA-EXPRESSING CANCERS KLK3, PSMA3, FOLH1 PLG 2410/4885PLAT 1232/4885LMNA 1491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.